Tatarstan Cancer Center, Kazan
Kamalov I.A. ― Cand. Med. Sc., oncologist of the Tatarstan Cancer Center
29 Sibirskiy Trakt, Kazan, Russian Federation, 420029, tel.: +7-917-267-55-11, (843) 519-27-03, e-mail: email@example.com
Abstract. To study the overall survival of patients with malignant neoplasms and concomitant venous thromboembolism, a prospective study was conducted. The main and control groups were homogeneous. The main group included patients with malignant neoplasms and concomitant venous thromboembolism. The control group was formed from patients with malignant neoplasms of similar homogeneous localizations. Initially, the patients of the control group had no venous thromboembolism. In the control group, venous thromboembolism were detected in 15% of the patients during the follow-up period. Patients were observed for two years. At the time of observation, distant metastases among the patients of the main group were detected 2.4 times more often than in the control group. Mortality in the main group was 42.1%, and in the control group the mortality was 20.8%. Venous thromboembolic complications are associated with the progression of malignant neoplasms and poor survival of cancer patients.
Кеу words: malignant neoplasms venous thromboembolism, distant metastases, mortality, survival.